From: Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
Variables | Â |
---|---|
Number of patients | 13 |
Male, n (%) | 5 (38%) |
Age, years | 62 ± 12 |
Body mass index, kg/m2 | 27 ± 5 |
Coronary risk factors | |
 Dyslipidemia, n (%) | 7 (54%) |
 Hypertension, n (%) | 8 (62%) |
 Current sumoker/past smoker | 0/3 (23%) |
Coronary artery disease | 4 (31%) |
 History of old myocardial infarction | 0 (0%) |
 History of PCI | 3 (23%) |
 History of CABG | 1 (8%) |
Anti-diabetic drugs | |
 DPP-4 inhibitors | 5 (38%) |
 α-Glucosidase inhibitors | 1 (8%) |
 Sulfonylureas | 1 (8%) |
 Biguanides | 1 (8%) |
 Glinides | 1 (8%) |
 Thizoladinediones | 0 (0%) |
 Insulin | 2 (15%) |
Statins | 7 (54%) |
Antihyperuricemics | 3 (23%) |